Skip to main content
Aardvark Therapeutics, Inc. logo

Aardvark Therapeutics, Inc. — Investor Relations & Filings

Ticker · AARD ISIN · US0029421007 US Manufacturing
Filings indexed 86 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country US United States of America
Listing US AARD

About Aardvark Therapeutics, Inc.

https://aardvarktherapeutics.com/

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel, small-molecule therapeutics. The company focuses on activating innate homeostatic pathways to address metabolic diseases and conditions associated with hunger. Its lead product candidate, ARD-101, is an oral investigational drug designed for the treatment of hyperphagia, particularly in rare genetic diseases. ARD-101 functions primarily within the digestive tract by activating bitter taste receptors (TAS2Rs), which triggers the local release of satiety hormones. These hormones then send signals to the brain to suppress hunger. The company aims to become a leader in treating hunger, with potential applications for obesity and related conditions.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-14 English
10-Q - Aardvark Therapeutics, Inc. (0001774857) (Filer)
Interim / Quarterly Report
2026-05-07 English
8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
Regulatory Filings
2026-05-07 English
8-K - AARDVARK THERAPEUTICS, INC. (0001774857) (Filer)
Regulatory Filings
2026-02-27 English
8-K Filing
Regulatory Filings
2026-02-12 English
4 Filing
Director's Dealing
2026-02-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.